Lilly reports durable first‑line activity of olomorasib in KRAS G12C‑mutant NSCLC at ESMO 2026
Eli Lilly presented updated Phase 1/2 and Phase 3 data for its investigational KRAS G12C inhibitor olomorasib combined with pembrolizumab, with or without chemotherapy, in first‑line non‑small cell lung cancer. In 85 patients receiving olomorasib plus pembrolizumab the median progression‑free survival and duration of response were not reached after a median follow‑up of 20.7 months, while a separate cohort of 77 patients receiving olomorasib plus chemo‑immunotherapy showed an overall response rate of 62% and a median progression‑free survival of 11.6 months (95% CI 9.5‑21.5). Lilly expects the first randomized Phase 3 data from the SUNRAY‑01 trial in the first half of 2027.
Why it matters
The data suggest olomorasib could become a first‑line option for KRAS G12C‑mutant NSCLC, a segment with no approved targeted therapies, potentially expanding Lilly’s oncology pipeline and driving future revenue. The company’s guidance that Phase 3 results are expected in H1 2027 signals a timeline for investors to assess commercial impact.
Key facts
- 1Olomorasib plus pembrolizumab was evaluated in 85 first‑line KRAS G12C‑mutant NSCLC patients, with 64% having PD‑L1 expression ≥50%. prnewswire.com
- 2In the same cohort, median duration of response and median progression‑free survival were not reached after a median follow‑up of 20.7 months. prnewswire.com
- 3Olomorasib plus chemo‑immunotherapy was evaluated in 77 first‑line patients, 74% with PD‑L1 expression <50%. prnewswire.com
- 4The investigator‑assessed overall response rate for the chemo‑immunotherapy combination was 62% (48/77). prnewswire.com
- 5Median progression‑free survival for the chemo‑immunotherapy combination was 11.6 months (95% CI 9.5‑21.5). prnewswire.com
- 6Median duration of response for the chemo‑immunotherapy combination was 14.5 months (95% CI 8.5‑NE). prnewswire.com
Summary written by AlphAI AI Desk from 7 of 7 sources. Not investment advice. Figures are as stated by the linked sources.